UCB Data Shows KYGEVVI® Dramatically Improves Survival in Rare Mitochondrial Disease

Event summary

  • UCB published data in Brain Communications showing KYGEVVI® reduced death risk by 92–94% in early-onset TK2d patients.
  • Treated patients lived an average of 29.2 years vs. 14.4 years for untreated patients.
  • 75% of treated patients regained at least one motor milestone post-treatment.
  • Diarrhea was the most common adverse event (86%), but generally mild or moderate.

The big picture

UCB’s data reinforces KYGEVVI as a breakthrough treatment for an ultra-rare disease with no prior approved therapies. The results could set a new benchmark for rare disease interventions, particularly in mitochondrial disorders. The strategic focus now shifts to ensuring early diagnosis and treatment access, as the data underscores the critical window for intervention in early-onset TK2d.

What we're watching

Market Expansion
Whether UCB can leverage these results to expand KYGEVVI’s market reach beyond early-onset TK2d.
Regulatory Dynamics
The pace at which additional regulatory approvals for KYGEVVI could accelerate its global availability.
Competitive Positioning
How this data positions UCB against potential future competitors in the TK2d treatment space.